CN102961408B - Toad skin extract dry powder inhaler - Google Patents
Toad skin extract dry powder inhaler Download PDFInfo
- Publication number
- CN102961408B CN102961408B CN201210557892.6A CN201210557892A CN102961408B CN 102961408 B CN102961408 B CN 102961408B CN 201210557892 A CN201210557892 A CN 201210557892A CN 102961408 B CN102961408 B CN 102961408B
- Authority
- CN
- China
- Prior art keywords
- cutis bufonis
- extract
- bufonis extract
- powder
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 118
- 229940112141 dry powder inhaler Drugs 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 246
- 239000000843 powder Substances 0.000 claims description 60
- OBRNDARFFFHCGE-QDSVTUBZSA-N arformoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-QDSVTUBZSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 25
- 239000006228 supernatant Substances 0.000 claims description 19
- 229960000193 formoterol fumarate Drugs 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 238000005507 spraying Methods 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 238000000703 high-speed centrifugation Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 52
- 238000002347 injection Methods 0.000 abstract description 36
- 239000007924 injection Substances 0.000 abstract description 36
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004072 lung Anatomy 0.000 abstract description 15
- 210000004185 liver Anatomy 0.000 abstract description 6
- 238000010579 first pass effect Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 22
- 239000008101 lactose Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 230000002685 pulmonary effect Effects 0.000 description 16
- 239000008187 granular material Substances 0.000 description 15
- 238000012869 ethanol precipitation Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 230000008021 deposition Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- -1 reflux Substances 0.000 description 8
- XFIMEMVNMWDPRW-UHFFFAOYSA-O C1=C(OS(O)=O)C([N+](C)(C)CC2)=C3C2=CNC3=C1 Chemical compound C1=C(OS(O)=O)C([N+](C)(C)CC2)=C3C2=CNC3=C1 XFIMEMVNMWDPRW-UHFFFAOYSA-O 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 208000037841 lung tumor Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000005325 percolation Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241001415440 Bufo gargarizans Species 0.000 description 3
- 241000269420 Bufonidae Species 0.000 description 3
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical class C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 241000269417 Bufo Species 0.000 description 2
- VOZHMAYHYHEWBW-UHFFFAOYSA-N Bufotalin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VOZHMAYHYHEWBW-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 208000007888 Sinus Tachycardia Diseases 0.000 description 2
- 206010040741 Sinus bradycardia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HDTHCLKLBSPBIS-JBXNKDOXSA-N (2s)-2-[[8-[[(3s,5r,8r,9s,10s,13r,14s,16s,17r)-16-acetyloxy-14-hydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-8-oxooctanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical class C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@@H](C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)OC(=O)CCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C=CC(=O)OC=1 HDTHCLKLBSPBIS-JBXNKDOXSA-N 0.000 description 1
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 229930190011 Bufogenin Natural products 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241001415432 Duttaphrynus melanostictus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 description 1
- 229950006858 bufogenin Drugs 0.000 description 1
- VTTONGPRPXSUTJ-UHFFFAOYSA-N bufotenin Chemical class C1=C(O)C=C2C(CCN(C)C)=CNC2=C1 VTTONGPRPXSUTJ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a dry powder inhaler and specifically relates to a dry powder inhaler produced by a toad skin extract, a preparation method of the dry powder inhaler and an application of the dry powder inhaler in preparation of medicaments for treating tumors of the lung. The toad skin extract dry powder inhaler is characterized by comprising the toad skin extract and pharmaceutically acceptable excipients, and the weight ratio of the toad skin extract to the excipients is (1:0)-(1:110). The dry powder inhaler produced by the toad skin extract can direct act on patients with lung diseases, reduce the occurrence of toxic and side effects, improve the bioavailability of the medicament, overcome the shortcomings of low effect taking speed, first-pass effect of the liver, systemic toxic and side effects, lower bioavailability and the like of oral preparations, and simultaneously solve the problems of inconvenience in use, poor patient compliance and the like of injections.
Description
technical field:
The present invention relates to Foradil Aerolizer formoterol fumarate, the Foradil Aerolizer formoterol fumarate that Cutis Bufonis extract is made specifically, the preparation method of described Foradil Aerolizer formoterol fumarate and the application in preparation treatment lung tumors medicine.
background technology:
Cinobufacin is the extract that the dry skin of Bufonidae (Bufonidae) animal Bufo siccus Bufobufo gargarizans Cantor makes through extracting purification, the effect with removing toxic substances, detumescence, pain relieving, in being used for the treatment of, the disease such as late tumor, chronic hepatitis B, its biological active substances is mainly bufotoxin class (bufotoxins) and hydrolyzate bufotalin class (bufageins), bufotenine class (bufoteinines) etc.Current cinobufacin injection, oral liquid, tablet have been applied to clinical, and hepatocarcinoma, pulmonary carcinoma, gastric cancer etc. are had to good curative effect.Especially HUACHANSU ZHUSHEYE, it is the water soluble preparation through being processed into from Skin of Bufo bufo gargarizans, treatment primary hepatocarcinoma and medium and advanced lung cancer obtain respectively 44% and 56% comprehensive effective percentage, and tumor body minification is respectively 10% and 16%, and chemotherapy and radiation is had to synergism.Although the clinical untoward reaction of HUACHANSU ZHUSHEYE is less, but still exist intravenous drip to there will be local vein reaction, cause that instillation vein shrinks spasm and causes pain, long-time stimulus causes vein nonspecific inflammation; Dermoreaction, main manifestations is urticaria and the infringement of skin blister sample; Secondly, there is the cardiovascular system reactions such as premature beat, sinus bradycardia, sinus tachycardia, atrioventricular block in small part patient, and the possible cause of generation is the cardiotoxicity that bufotalin a small amount of in cinobufacin produces.In addition, injection need to be used in hospital, and patient compliance is poor.And cinobufacin oral formulations need be through the first pass effect of liver, onset is slow, and preparation bioavailability is lower.
Lung has great surface area, and alveolar wall is comprised of cell monolayer, make drug molecule very easily enter blood, so lung inhalation has the plurality of advantages such as rapid-action, untoward reaction is little.(the drypowder inhalers of Foradil Aerolizer formoterol fumarate in lung inhalation, DPIs) do not use propellant and solvent, the air-flow producing by patient's autonomous respiration makes drug powder atomization, and then make drug powder be delivered to pulmonary, have application convenient, absorb rapidly, without liver firstly cross, the feature of rapid release and targeting location, be a kind of novel drug-supplying system.
The sickness rate of pulmonary carcinoma rises rapidly in worldwide, has become first of the cancer cause of the death.Current antitumor drug great majority are all drug administration by injection, and this whole body administering mode is unfavorable for that drug accumulation is in tumor locus, cause the curative effect of medicine to reduce, and untoward reaction increases.
Adopt site-specific delivery of drugs antitumor drug to be transported to the tumor patient part of human body, medicine is improved in the concentration of patient part, the toxic and side effects of reduction medicine is had to great clinical value, improve the therapeutic effect of medicine.Employing can directly be transmitted Cutis Bufonis extract the focus of pulmonary carcinoma through the inhalant of lung administering mode, is conducive to improve Cutis Bufonis extract to the curative effect of pulmonary carcinoma and reduces the toxic and side effects of its normal tissue.The research at present with the Cutis Bufonis extract Foradil Aerolizer formoterol fumarate of resisting tumor of lung effect has no report.
summary of the invention:
Goal of the invention: an object of the present invention is to provide pulmonary's dry powder inhaler formulations of Cutis Bufonis extract and preparation method thereof.Another object of the present invention is to provide the application of Foradil Aerolizer formoterol fumarate of the present invention in preparation treatment lung tumors medicine.
For foregoing invention object, the invention provides following technical scheme:
A Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, is characterized in that it is comprised of Cutis Bufonis extract and medically acceptable adjuvant, and Cutis Bufonis extract (according to gained solids quality after dry) is 1:0-1:110 with the mass ratio of described adjuvant.
Described a kind of Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, is the powder that adds adjuvant to make by Cutis Bufonis extract, and powder agglomeration forms re-dispersable particles; Or Cutis Bufonis extract loads on granules of accessories surface formation granule; The particle diameter of above-mentioned two kinds of granules is with D
50meter is between 0.5-1000 micron.
Described Cutis Bufonis extract, the extract making through extracting purification for the skins of Bufonidae animal Bufo siccus or Bufo melanostictus etc.The preparation method of Cutis Bufonis extract is:
Get 1 part of Cutis Bufonis, add 2-100 times of water gaging, backflow or decoction or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, at every turn 0.1-48 hour, merge water extraction liquid, being concentrated into relative density is 1.01-1.50(60-100 ℃), add ethanol (65%-100%, W/W) precipitation, make ethanol content reach 50%(W/W) more than, standing or centrifugal or filtration treatment, gets supernatant and reclaims ethanol, obtain Cutis Bufonis extract or concentrated, dry after obtain Cutis Bufonis extract.
Or, get 1 part of Cutis Bufonis, add 2-100 times of water gaging, backflow or decoction or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge water extraction liquid, being concentrated into relative density is 1.01-1.50(60-100 ℃), add ethanol (65%-100%, W/W) precipitation, make ethanol content reach 50%(W/W) more than, standing or centrifugal or filtration treatment, get supernatant and reclaim ethanol extremely without alcohol taste, add ethanol (65%-100%, W/W) precipitation, make ethanol content reach 60%(W/W) more than, standing or centrifugal or filtration treatment, get supernatant and reclaim ethanol extremely without alcohol taste, obtain Cutis Bufonis extract or concentrated, after dry, obtain Cutis Bufonis extract.
Or, get 1 part of Cutis Bufonis, add 2-100 times of water gaging, backflow or decoction or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge water extraction liquid, through the ultrafilter membrane ultrafiltration of molecular weight 500-5000, obtain Cutis Bufonis extract or concentrated, dry after obtain Cutis Bufonis extract.
Or, get 1 part of Cutis Bufonis, add the certain density ethanol (1%-100%, W/W) that 2-100 doubly measures, reflux or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge extractive liquid,, reclaims ethanol to without alcohol taste, adds 0-100 times of water, standing or centrifugal or filtration treatment, obtain Cutis Bufonis extract or concentrated, dry after obtain Cutis Bufonis extract.
Or, get 1 part of Cutis Bufonis, add the certain density ethanol (1%-100%, W/W) that 2-100 doubly measures, reflux or ultrasonic or microwave or lixiviate or percolation extract 1-10 time, each 0.1-48 hour, merge extractive liquid,, reclaims ethanol to without alcohol taste, adds 0-100 times of water, through the ultrafilter membrane ultrafiltration of molecular weight 500-5000, obtain Cutis Bufonis extract or concentrated, dry after obtain Cutis Bufonis extract.
Described adjuvant is selected one or more mixture in sugar, alcohol, aminoacid, phospholipid, surfactant, cyclodextrin, polymer substance, magnesium stearate, stearic acid, hard ester fumaric acid sodium, micropowder silica gel, Pulvis Talci.
Described sugar, can select one or more mixture in galactose, lactose, glucose, fructose, sucrose, trehalose, Raffinose; Described alcohol, can select one or more mixture in mannitol, xylitol, maltose alcohol, sorbitol; Described aminoacid, can select one or more in glycine, Aspartic Acid, alanine, tryptophan, isoleucine, threonine, glutamic acid, phenylalanine, leucine, cystine, lysine, proline, arginine; Described phospholipid, can select one or more in soybean phospholipid, lecithin, phosphatidylcholine, PHOSPHATIDYL ETHANOLAMINE, synthetic phospholipid; Described surfactant, can select pulmonary surfactant as one or more mixture in dipalmitoyl phosphatidyl choline, DLPC, cholesterol; Described polymer substance, can select the macromolecule that meets safety requirements, preferred biodegradable polymer substance is one or more mixture in albumin, starch, polylactic acid, poly lactic-co-glycolic acid, Polyethylene Glycol, poloxamer, hyaluronic acid, hyaluronate sodium, sodium alginate for example.
Preferred mode is described adjuvant for sucking by lactose granule mean diameter the mixture at 1-10 micron in 45-220 micron and micronization lactose mean diameter, and wherein the mass ratio of lactose granule and micronization lactose is 1000:1-1:1.Most preferred mode is that the mass ratio of lactose granule and micronization lactose is 100:1-7:1.
A method of preparing Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, its preparation process is as follows:
Cutis Bufonis extract, by pulverizing or spraying to be dried and make powder, is packaged in capsule or bubble-cap or Diskus; By Cutis Bufonis extract, by pulverizing or spraying to be dried and make powder, powder is mixed homogeneously and is made suction powder with adjuvant, is packaged in capsule or bubble-cap or Diskus; Or Cutis Bufonis extract is mixed homogeneously with adjuvant, by pulverizing or spraying to be dried and make suction powder, be packaged in capsule or bubble-cap or Diskus; Or by partial supplementary material mix homogeneously in Cutis Bufonis extract and prescription, by pulverizing or spray the dry powder of making, powder with write out a prescription in remain adjuvant and mix homogeneously and make suction powder, be packaged in capsule or bubble-cap or Diskus.
A method of preparing Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, its preparation process is as follows:
By Cutis Bufonis extract, by pulverizing or spraying to be dried and make powder, powder is mixed homogeneously with adjuvant, reunites and forms re-dispersable particles, is packaged in capsule or bubble-cap or Diskus; Or Cutis Bufonis extract is mixed homogeneously with adjuvant, by pulverizing or spray the dry powder of making, reunite and form re-dispersable particles, be packaged in capsule or bubble-cap or Diskus; Or by partial supplementary material mix homogeneously in Cutis Bufonis extract and prescription, by pulverizing or spray the dry powder of making, powder with in prescription, remain adjuvant and mix homogeneously, the formation re-dispersable particles of reuniting, is packaged in capsule or bubble-cap or Diskus; Or by pulverizing or spray the dry powder of making, powder load forms granule on granules of accessories surface, is packaged in capsule or bubble-cap or Diskus by Cutis Bufonis extract.
The application of a kind of Cutis Bufonis extract Foradil Aerolizer formoterol fumarate in preparing lung tumors medicine.
beneficial effect:
1, lung has great surface area, and alveolar wall is comprised of cell monolayer, make drug molecule very easily enter blood, so lung inhalation has the plurality of advantages such as rapid-action, untoward reaction is little.(the drypowder inhalers of Foradil Aerolizer formoterol fumarate in lung inhalation, DPIs) do not use propellant and solvent, the air-flow producing by patient's autonomous respiration makes drug powder atomization, and then make drug powder be delivered to pulmonary, have application convenient, absorb rapidly, without liver firstly cross, the feature of rapid release and targeting location, be a kind of novel drug-supplying system.At present relevant for Foradil Aerolizer formoterol fumarate, be used for treating the infection of respiratory tract and pulmonary, but have no the treatment at lung tumors.Meanwhile, the research that has a Cutis Bufonis extract Foradil Aerolizer formoterol fumarate of resisting tumor of lung effect also has no report.Current Cutis Bufonis extract injection, oral liquid, tablet have been applied to clinical, and hepatocarcinoma, pulmonary carcinoma, gastric cancer etc. are had to good effect.Especially HUACHANSU ZHUSHEYE, it is the water soluble preparation through being processed into from Skin of Bufo bufo gargarizans, treatment primary hepatocarcinoma and medium and advanced lung cancer obtain respectively 44% and 56% comprehensive effective percentage, and tumor body minification is respectively 10% and 16%, and chemotherapy and radiation is had to synergism.Although the clinical untoward reaction of HUACHANSU ZHUSHEYE is less, but still exist intravenous drip to there will be local vein reaction, cause that instillation vein shrinks spasm and causes pain, long-time stimulus causes vein nonspecific inflammation; Dermoreaction, main manifestations is urticaria and the infringement of skin blister sample; Secondly, there is the cardiovascular system reactions such as premature beat, sinus bradycardia, sinus tachycardia, atrioventricular block in small part patient, and the possible cause of generation is the cardiotoxicity that bufotalin a small amount of in cinobufacin produces.In addition injection need to be used in hospital, and patient compliance is poor.And Cutis Bufonis extract oral formulations need be through the first pass effect of liver, onset is slow, and preparation bioavailability is lower.Using the Foradil Aerolizer formoterol fumarate of Cutis Bufonis extract is mainly for lung tumors, directly acts on affected part, does not have the first pass effect of liver simultaneously, rapid-action, and there is no above-mentioned untoward reaction, and new drug development is had to great prospect.
2, because Cutis Bufonis extract is mixture, wherein contain indole alkaloids, cinobufagin, bufogenin etc., in practical operation, find, while adding the specific adjuvant of certain proportioning can overcome extract to be crushed to certain particle diameter and the reunion that the electrostatic interaction producing, cohesiveness etc. cause reduces hygroscopicity.Applicant passes through great many of experiments to be known, particularly adjuvant is selected the mixture of lactose granule and micronization lactose or adopted powder agglomeration technology can make the good Foradil Aerolizer formoterol fumarate of intake performance.
The specific embodiment
Below in conjunction with example, the present invention is described in further detail, but scope of the present invention is not subject to any restriction of these examples.
Embodiment 1
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 10 times of water gagings, decoct 2 times, each 1.5 hours, merging filtrate, being concentrated into relative density is 1.1-1.2 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 60% containing alcohol amount, standing 24 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filter, reclaim ethanol to thick paste, 60 ℃ dry, obtains Cutis Bufonis extract.
2, the preparation of inhalant: adopt comminution by gas stream to D Cutis Bufonis extract
50below 5 microns, with particle diameter the lactose of 45-70 micron in mass ratio 1:10 mix, drug powder is packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 2
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 12 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 70% containing alcohol amount, standing 24 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, spraying is dry, obtains Cutis Bufonis extract powder, powder D
50below 5 microns.
2, the preparation of inhalant: by Cutis Bufonis extract powder, particle diameter the lactose of 45-80 micron, particle diameter the leucine of 20-50 micron in mass ratio the ratio of 10:100:1 mix, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 3
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 30 times of water gagings, microwave-assisted extracts 3 times, each 1 hour, merge extractive liquid,, through the ultrafilter membrane ultrafiltration of molecular weight 1000, the dry Cutis Bufonis extract powder, powder D of obtaining of ultrafiltrate spraying
50below 5 microns.
2, the preparation of inhalant: Cutis Bufonis extract powder packets is packed in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 4
1, the ethanol preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add 12 times of amount 60%(W/W), reflux, extract, 2 times, each 2 hours, merge extractive liquid,, reclaims ethanol extremely without alcohol taste, deepfreeze 48 hours, filter, add 0.3% active carbon (W/V), boil 30 minutes, filter, spraying is dry, obtains Cutis Bufonis extract powder.
2, the preparation of inhalant: by Cutis Bufonis extract powder, lactose, mannitol, glycine, DLPC, lecithin, magnesium stearate in mass ratio the ratio of 1:5:5:2:0.5:0.5:0.1 mix, comminution by gas stream is to powder D
50below 5 microns, drug powder is packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 5
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, the dehydrated alcohol that adds 20 times of amounts, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, reclaimed ethanol, ultrafilter membrane ultrafiltration through molecular weight 3000, ultrafiltrate vacuum concentration to proportion is 1.20 (45 ℃), and 50 ℃ of vacuum dryings of extractum, obtain Cutis Bufonis extract.
2, the preparation of inhalant: Cutis Bufonis extract, lactose, cholesterol are mixed in the ratio of 1:8:1, and comminution by gas stream is to powder D
50below 5 microns, drug powder is packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 6
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 60%(W/W of 15 times of amounts) ethanol, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, reclaims ethanol extremely without alcohol taste, and it is heavy that concentrated solution adds 2 times of water gagings, standing 24 hours, high speed centrifugation, got supernatant and obtains Cutis Bufonis extract.
2, the preparation of inhalant: respectively lactose, polyethylene glycol 6000, the albumin of 5 times, 1 times, 2 times of contained solid qualities in above-mentioned Cutis Bufonis extract are added in Cutis Bufonis extract, spraying is dry, powder D
50below 5 microns, drug powder is packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 7
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 10%(W/W of 10 times of amounts) ethanol, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, reclaims ethanol extremely without alcohol taste, and concentrated solution high speed centrifugation, gets supernatant and obtain Cutis Bufonis extract, spraying is dry, obtains Cutis Bufonis extract, powder D
50below 5 microns.
2, the preparation of inhalant: by Cutis Bufonis extract drug powder, particle diameter the mannitol of 10-90 micron, micronization silica gel in mass ratio the ratio of 10:89:1 mix, after mix homogeneously, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 8
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 50%(W/W of 10 times of amounts) ethanol, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, reclaims ethanol extremely without alcohol taste, concentrated solution high speed centrifugation, get supernatant and obtain Cutis Bufonis extract, spraying is dry, obtains Cutis Bufonis extract powder.
2, the preparation of inhalant: by Cutis Bufonis extract drug powder, mannitol, leucine in mass ratio the ratio of 10:100:3 mix, after mixing, add water appropriate, the dry D that obtains of spraying
50be the powder of 4.8 microns, with there being the rotary blender of polymer inner liner to mix, make loose aggregate, the D of aggregate
50be 390 microns, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 9
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add the 40%(W/W of 10 times of amounts) ethanol, reflux, extract, 3 times, each 0.5 hour, merge extractive liquid,, reclaims ethanol extremely without alcohol taste, concentrated solution high speed centrifugation, get supernatant and obtain Cutis Bufonis extract, spraying is dry, powder D
50below 5 microns.
2, the preparation of inhalant: by Cutis Bufonis extract powder, mannitol, leucine in mass ratio the ratio of 10:80:2 mix, with there being the rotary blender of polymer inner liner to mix, make loose aggregate, the D of aggregate
50be 120 microns, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 10
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 20 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 70% containing alcohol amount, standing 24 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, spraying is dry, powder D
50below 5 microns.
2, the preparation of inhalant: by Cutis Bufonis extract powder, happy InhaLac 70 lactose of German U.S. agent, micronization lactose (D
50=5.1 microns) in mass ratio the ratio of 5:90:5 mix, after mix homogeneously, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
3, inhalant pulmonary deposition ratio is investigated
According to People's Republic of China's version pharmacopeia prescriptive procedure in 2010, investigate, with bufothionine content meter in preparation, its pulmonary deposition ratio reaches 32.6%, under room temperature condition, places after 18 months, and in preparation, the pulmonary deposition ratio of bufothionine does not have significant change.
Embodiment 11
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 20 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 70% containing alcohol amount, standing 24 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, spraying is dry, powder D
50below 5 microns.
2, the preparation of inhalant: by Cutis Bufonis extract powder, happy InhaLac 70 lactose of German U.S. agent, micronization lactose (D
50=4.9 microns) in mass ratio the ratio of 3:95:1 mix, after mix homogeneously, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
3, inhalant pulmonary deposition ratio is investigated
According to People's Republic of China's version pharmacopeia prescriptive procedure in 2010, investigate, with bufothionine content meter in preparation, its pulmonary deposition ratio reaches 30.2%, under room temperature condition, places after 18 months, and in preparation, the pulmonary deposition ratio of bufothionine does not have significant change.
Embodiment 12
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 20 times of water gagings, decoct 2 times, each 2 hours, merging filtrate, being concentrated into relative density is 1.2-1.3 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 70% containing alcohol amount, standing 24 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, spraying is dry, powder D
50below 5 microns.
2, the preparation of inhalant: by Cutis Bufonis extract powder, happy InhaLac 70 lactose of German U.S. agent, micronization lactose (D
50=5.5 microns) in mass ratio the ratio of 3:77:11 mix, after mix homogeneously, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
3, inhalant pulmonary deposition ratio is investigated
According to People's Republic of China's version pharmacopeia prescriptive procedure in 2010, investigate, with bufothionine content meter in preparation, its pulmonary deposition ratio reaches 29.8%, under room temperature condition, places after 18 months, and in preparation, the pulmonary deposition ratio of bufothionine does not have significant change.
Embodiment 13
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 10 times of water gagings, decoct 2 times, each 1 hour, merging filtrate, being concentrated into relative density is 1.3-1.4 (85 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 60% containing alcohol amount, standing 48 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 80% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, spraying is dry, powder D
50below 5 microns.
2, the preparation of inhalant: Cutis Bufonis extract powder, leucine are mixed to the D of granule after mixing in the ratio of 1:5
50be 292 microns, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 14
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 6 times of water gagings, decoct 5 times, each 1 hour, merging filtrate, being concentrated into relative density is 1.05 (70 ℃), be cooled to 40 ℃, add ethanol precipitation, make to reach 65% containing alcohol amount, standing 48 hours, to get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 70% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, concentrating under reduced pressure, vacuum drying obtains Cutis Bufonis extract.
2, the preparation of inhalant: Cutis Bufonis extract is mixed to comminution by gas stream, powder D with leucine in the ratio of 1:1
50below 5 microns, this powder is mixed again to the D of granule after mixing with the mannitol of 9 times of amounts
50be 328 microns, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 15
1, the preparation of Cutis Bufonis extract: get dry maxima skin and clean, add 30 times of water gagings, decoct 1 hour, it is 1.30 (60 ℃) that extracting solution is concentrated into relative density, is cooled to 20 ℃, adds ethanol precipitation, make to reach 70% containing alcohol amount, standing 24 hours, get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 90% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, concentrating under reduced pressure, vacuum drying obtains Cutis Bufonis extract.
2, the preparation of inhalant: by Cutis Bufonis extract and poloxamer in mass ratio the ratio of 10:1 mix, comminution by gas stream, powder D
50below 5 microns, this powder is mixed again to the D of granule after mixing with the lactose granule of 8 times of amounts, the magnesium stearate of 1 times of amount
50be 653 microns, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 16
1, the preparation of Cutis Bufonis extract: get Cutis Bufonis and clean, add 10 times of water gagings, decoct 1 hour, it is 1.20 (50 ℃) that extracting solution is concentrated into relative density, is cooled to room temperature, adds ethanol precipitation, make to reach 50% containing alcohol amount, standing 24 hours, get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 70% containing alcohol amount, standing 48 hours, filter, reclaim ethanol extremely without alcohol taste, concentrating under reduced pressure, vacuum drying obtains Cutis Bufonis extract.
2, the preparation of inhalant: by Cutis Bufonis extract comminution by gas stream, powder D
50below 5 microns, this powder is mixed again to the D of granule after mixing with the lactose granule of 20 times of amounts
50be 286 microns, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Embodiment 17
According to embodiment 1-16, obtain inhalant, carry out pharmacodynamic experiment, wherein drugs compared is HUACHANSU ZHUSHEYE (commercially available), Cutis Bufonis injection A and B, and Cutis Bufonis injection A and B are prepared in accordance with the following methods:
Cutis Bufonis injection A:
Get dry maxima skin and clean, add 15 times of water gagings, decoct each 2 hours 2 times, merging filtrate, being concentrated into relative density is 1.2 (85 ℃), is cooled to 20 ℃, adds ethanol precipitation, make to reach 60% containing alcohol amount, standing 24 hours, get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filters, reclaim ethanol to without alcohol taste, add water to every milliliter and be equivalent to crude drug in whole 5g, regulate pH to 6.5,0.45 micron of membrane filtration, embedding, pressure sterilizing and get final product.
Cutis Bufonis injection B:
Get dry maxima skin and clean, add 20 times of amount 60% ethanol, reflux, extract, 2 times, each 2 hours, merge extractive liquid,, reclaimed ethanol extremely without alcohol taste, add 3 times of water gagings, deepfreeze 48 hours, filters, add 0.3% active carbon (W/V), boil 30 minutes, filter, add water to every milliliter and be equivalent to crude drug in whole 5g, regulate pH to 7,0.45 micron of membrane filtration, embedding, pressure sterilizing and get final product.
Effect experiment:
The method of benzopyrene percutaneous puncture pulmonary injection is set up induced lung animal model for tumour, gets 200 of modeling rats, is divided at random 20 groups, 10 every group.Every day 1 time, medication 7 days.Administering mode: 1-16 group is the inhalant inhalation of embodiment 1-16, and dosage is 15g crude drug/kg; The 17th group of lumbar injection HUACHANSU ZHUSHEYE (commercially available), dosage: 15g crude drug/kg; The 18th group of lumbar injection Cutis Bufonis injection A, dosage: 15g crude drug/kg; The 19th group of lumbar injection Cutis Bufonis injection B, dosage: 15g crude drug/kg; The 20th group is physiology saline control group, lumbar injection 10mL/kg.Next day is put to death rat in drug withdrawal, dissects lungs, observes lung lesion situation.
Experimental result: the pulmonary of rat of each group of inhalant administration occur the incidence rate of lump or nodular lesion minimum be 10.5%, be up to 30.3%; HUACHANSU ZHUSHEYE group (commercially available) is 60.5%, Cutis Bufonis injection A group is 50.1%, Cutis Bufonis injection B group is 60.8%, normal saline group is 100%, and each group of inhalant administration has significant difference (P<0.05) with HUACHANSU ZHUSHEYE group (commercially available), Cutis Bufonis injection A group, Cutis Bufonis injection B group, normal saline group in pulmonary lesion incidence rate.
Embodiment 18
According to embodiment 1-16, obtain inhalant, carry out pharmacodynamic experiment, wherein drugs compared is HUACHANSU ZHUSHEYE (commercially available), Cutis Bufonis injection A and B, and Cutis Bufonis injection A and B are prepared in accordance with the following methods:
Cutis Bufonis injection A:
Get dry maxima skin and clean, add 15 times of water gagings, decoct each 2 hours 2 times, merging filtrate, being concentrated into relative density is 1.2 (85 ℃), is cooled to 20 ℃, adds ethanol precipitation, make to reach 60% containing alcohol amount, standing 24 hours, get supernatant and reclaim ethanol extremely without alcohol taste, concentrated solution adds ethanol to be made to reach 85% containing alcohol amount, standing 48 hours, filters, reclaim ethanol to without alcohol taste, add water to every milliliter and be equivalent to crude drug in whole 5g, regulate pH to 6.5,0.45 micron of membrane filtration, embedding, pressure sterilizing and get final product.
Cutis Bufonis injection B:
Get dry maxima skin and clean, add 20 times of amount 60% ethanol, reflux, extract, 2 times, each 2 hours, merge extractive liquid,, reclaimed ethanol extremely without alcohol taste, add 3 times of water gagings, deepfreeze 48 hours, filters, add 0.3% active carbon (W/V), boil 30 minutes, filter, add water to every milliliter and be equivalent to crude drug in whole 5g, regulate pH to 7,0.45 micron of membrane filtration, embedding, pressure sterilizing and get final product.
Effect experiment:
1, the foundation of rabbit VX2 original position lung cancer model
1) the freezing cell suspension of the conventional recovery VX2 tumor of the making of lotus tumor kind rabbit, makes 10
6the living cells suspension of/mL, gets 1mL and is inoculated in intramuscular outside 1 rabbit right rear leg, after 3 weeks, in inoculation position, can lay one's hand on and the lump of a diameter 30cm, makes lotus tumor kind rabbit.
2) under aseptic condition, cut intramuscular tumor outside lotus tumor kind rabbit leg preparing of piece of tissue suspension, get and be the eugonic tumor tissues of flesh of fish sample, be cut into mud shape.RPMI 1640 culture fluid rinse 30 mesh sieves, remove individual cells and too small piece of tissue, and on sieve, part is crossed 20 mesh sieves under RPMI RPMI-1640 rinses, and removes excessive piece of tissue.Get lower part of screen and divide, after centrifugation, taking precipitate 2mL, adds RPMI RPMI-1640 and is mixed with piece of tissue suspension 20mL.
3) all rabbit right thoracic wall depilations of inoculation in lung, intramuscular injection speed is slept after new mixture 0.8mL/kg anaesthetizes and is fixed, routine disinfection, get aseptic three way cock, connecing respectively No. 12 injection needles, suctions has 1mL syringe Ji Xiyou VX2 tumor tissue's suspension of rabbit self blood clot or the syringe of cell suspension 1mL.Under X-ray examination, No. 12 syringe needles are thrust in rabbit inferior lobe of right lung, after resorption depletion of blood, inject 0.4mL piece of tissue suspension or cell suspension, then inject 0.2mL rabbit self blood clot, extract syringe needle, inoculate complete.
4) the whole rabbit of the observation of growth of xenografted situation were from after inoculation the 3rd day, and carry out to chest the CT scan that layer is wide, bed thickness is 5mm every day, observed transfer case in tumor growth, thoracic cavity.
5) rabbit VX2 original position lung cancer model is set up result rabbit all tumor growth in lung, success ratio of inoculation 100%.
2, effect experiment:
Get successfully 200 of modeling rabbit, be divided at random 20 groups, 10 every group.Every day 1 time, medication 12 days.Administering mode: 1-16 group is the inhalant inhalation of embodiment 1-16, dosage: 15g crude drug/kg; The 17th group of lumbar injection HUACHANSU ZHUSHEYE (commercially available), dosage: 15g crude drug/kg; The 18th group of lumbar injection Cutis Bufonis injection A, dosage: 15g crude drug/kg; The 19th group of lumbar injection Cutis Bufonis injection B, dosage: 15g crude drug/kg; The 20th group is physiology saline control group, lumbar injection 10mL/kg.Next day is put to death rabbit in drug withdrawal, dissects rabbit lungs, peels off tumor tissues, weighs.
Experimental result: the tumour inhibiting rate minimum of the rabbit of each group of inhalant administration is 58.7%, is up to 64.3%; HUACHANSU ZHUSHEYE group (commercially available) is 56.3%, Cutis Bufonis injection A group is 45.1%, Cutis Bufonis injection B group is 48.9%, normal saline is to almost unrestraint effect of tumor, and each group of inhalant administration has significant difference (P<0.05) with the tumour inhibiting rate of HUACHANSU ZHUSHEYE group (commercially available), Cutis Bufonis injection A group, Cutis Bufonis injection B group, normal saline group.
Claims (1)
1. a Cutis Bufonis extract Foradil Aerolizer formoterol fumarate, is characterized in that it is comprised of Cutis Bufonis extract and medically acceptable adjuvant;
Being prepared as of described Cutis Bufonis extract: get Cutis Bufonis and clean, add 10% ethanol of 10 times of amounts, reflux, extract, 2 times, each 1 hour, merge extractive liquid,, reclaims ethanol extremely without alcohol taste, and concentrated solution high speed centrifugation, gets supernatant and obtain Cutis Bufonis extract, spraying is dry, obtains Cutis Bufonis extract, powder D
50below 5 microns;
Being prepared as of described inhalant: by Cutis Bufonis extract drug powder, particle diameter the mannitol of 10-90 micron, micronization silica gel in mass ratio the ratio of 10:89:1 mix, after mix homogeneously, be packaged in capsule or bubble-cap or Diskus, obtain inhalant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210557892.6A CN102961408B (en) | 2011-06-02 | 2011-06-02 | Toad skin extract dry powder inhaler |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210557892.6A CN102961408B (en) | 2011-06-02 | 2011-06-02 | Toad skin extract dry powder inhaler |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101478093A Division CN102210712B (en) | 2011-06-02 | 2011-06-02 | Bufo bufo gargarizans cantor skin extract dry powder inhalant and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102961408A CN102961408A (en) | 2013-03-13 |
| CN102961408B true CN102961408B (en) | 2014-07-16 |
Family
ID=47792027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210557892.6A Expired - Fee Related CN102961408B (en) | 2011-06-02 | 2011-06-02 | Toad skin extract dry powder inhaler |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961408B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813802A (en) * | 2005-02-04 | 2006-08-09 | 安徽金蟾生化股份有限公司 | Bufonid skin extract production process |
-
2011
- 2011-06-02 CN CN201210557892.6A patent/CN102961408B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813802A (en) * | 2005-02-04 | 2006-08-09 | 安徽金蟾生化股份有限公司 | Bufonid skin extract production process |
Non-Patent Citations (4)
| Title |
|---|
| 华蟾素雾化吸入治疗慢性阻塞性肺病的初步研究;晁耀烁等;《中华实用中西医杂志》;20050430;第18卷(第4期);第526-527页 * |
| 影响干粉吸入剂肺沉积的制剂因素;王晓波等;《中国新药杂志》;20100731;第19卷(第7期);第581-582页 * |
| 晁耀烁等.华蟾素雾化吸入治疗慢性阻塞性肺病的初步研究.《中华实用中西医杂志》.2005,第18卷(第4期),第526-527页. |
| 王晓波等.影响干粉吸入剂肺沉积的制剂因素.《中国新药杂志》.2010,第19卷(第7期),第581-582页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102961408A (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107789340A (en) | A kind of Herba Andrographitis Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN102078312A (en) | Curcumin compound dry powder inhaler as well as preparation method and application thereof | |
| CN102058566A (en) | Dry powder inhaler with constituent rubescensin A as well as preparation method and application thereof | |
| CN102961409B (en) | Toad skin extract dry powder inhaler | |
| CN102210712B (en) | Bufo bufo gargarizans cantor skin extract dry powder inhalant and preparation method and use thereof | |
| CN102247335B (en) | Bufalin dry powder inhalant as well as preparation method and application thereof | |
| CN102961406B (en) | Toad skin extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102302475B (en) | Resibufogenin dry powder inhalant and preparation method and application thereof | |
| CN102302477B (en) | Cinobufagin dry power inhaler and preparation method and application thereof | |
| CN103083286B (en) | Toad venom lipophilic extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102210711B (en) | Senso fat-soluble extract dry powder inhalation, preparation method and application thereof | |
| CN102961407B (en) | Toad skin extract dry powder inhaler, as well as preparation method and application thereof | |
| CN102961408B (en) | Toad skin extract dry powder inhaler | |
| CN103070885B (en) | Toad skin extract dry-powder inhalant and its preparation method and use | |
| CN103070886B (en) | Toad skin extract dry-powder inhalant and its preparation method and use | |
| CN102973605B (en) | Toad skin extract dry powder inhalant and preparation method and applications thereof | |
| CN102973604B (en) | Toad skin extract dry powder inhalant and preparation method and applications thereof | |
| CN102988419A (en) | Toad skin extract powder inhalant, and preparation method and application thereof | |
| CN102247336B (en) | Bufothionine dry powder inhaler, and its preparation method and application | |
| CN103142652B (en) | Venenum bufonis fat-soluble extract dry powder inhaler, and preparation method and application thereof | |
| CN101623286B (en) | Transdermal administration composite containing cucurbitacin-type active ingredient | |
| CN102247337B (en) | Bufotalin dry powder inhalers and preparation method as well as application thereof | |
| CN114432329A (en) | Application of geniposide in preparation of medicine for treating psoriasis | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN102302476B (en) | Dehydrobufotenine dry power inhaler and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140716 |